QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
QIAGEN N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$46.55+0.42 (+0.91%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 24.0
- Dividend yield
- 0.54%
QIAGEN N.V. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumables and related revenues | $1.88B | $1.76B | $1.73B | – | – | – | $1.35B | $1.32B | $1.24B | $1.17B | 89.8% | +6.6% |
| Diagnostic solutions | $803.08M | $748.89M | $697.63M | $660.88M | $638.76M | $460.76M | $465.50M | $461.06M | – | – | 38.4% | +7.2% |
| Sample technologies | $661.27M | $642.03M | $662.99M | $796.93M | $850.64M | $803.87M | $548.37M | $546.64M | – | – | 31.6% | +3.0% |
| PCR/Nucleic acid amplification | $308.99M | $300.47M | $300.20M | $390.80M | $433.97M | $363.55M | $224.69M | $236.95M | – | – | 14.8% | +2.8% |
| Genomics/NGS | $241.78M | $233.61M | $238.91M | $224.80M | $245.07M | $165.57M | $183.77M | $163.38M | – | – | 11.6% | +3.5% |
| Instruments | $213.58M | $217.98M | $239.10M | – | – | – | $172.28M | $186.39M | $174.82M | $171.86M | 10.2% | -2.0% |
| Other | $74.89M | $53.22M | $65.58M | $68.11M | $83.22M | $76.60M | $104.10M | $93.81M | – | – | 3.6% | +40.7% |
| Instrumentation | – | – | – | – | – | – | – | – | $174.82M | $171.86M | – | – |
| Consumables and related revenues | – | – | – | – | – | – | – | – | $1.24B | $1.17B | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Americas | $1.09B | $1.03B | $1.02B | $997.76M | $1.01B | $825.46M | $721.99M | $693.02M | $653.38M | $627.47M | 52.0% | +5.3% |
| United States | $998.45M | $942.01M | $935.28M | $909.62M | $909.69M | $728.58M | $663.87M | $632.66M | $579.91M | $555.68M | 47.8% | +6.0% |
| Europe, Middle East and Africa | $712.76M | $648.49M | $624.57M | $733.47M | $814.42M | $682.29M | $487.48M | $490.30M | $462.98M | $428.06M | 34.1% | +9.9% |
| Asia Pacific, Japan and Rest of World | $290.73M | $298.15M | $320.68M | $410.29M | $429.86M | $362.60M | $316.96M | $318.53M | $301.17M | $282.46M | 13.9% | -2.5% |
| Other Americas | $88.07M | $89.56M | $84.77M | $88.14M | $97.69M | $96.88M | $58.12M | $60.36M | $73.48M | $71.80M | 4.2% | -1.7% |
| Netherlands | $23.70M | $20.90M | $20.30M | $31.50M | $28.30M | $17.80M | $15.80M | $15.90M | $15.00M | $12.40M | 1.1% | +13.4% |
From the segment and revenue-disaggregation notes of Qiagen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.